Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 166

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

MYC and BCL 2 protein expression predicts survival in patients with diffuse large B‐cell lymphoma treated with rituximab

Perry, Anamarija M., Alvarado‐Bernal, Yuridia, Laurini, Javier A., Smith, Lynette M., Slack, Graham W., Tan, King L., Sehn, Laurie H., Fu, Kai, Aoun, Patricia, Greiner, Timothy C., Chan, Wing C., Bierman, Philip J., Bociek, Robert G., Armitage, James O., Vose, Julie M., Gascoyne, Randy D., Weisenburger, Dennis D. · 2014 · British Journal of Haematology

Abstract

Summary: Diffuse large B‐cell lymphoma (DLBCL) is a heterogeneous disease and “double‐hit” DLBCL, with both MYC and BCL 2 translocations has a poor prognosis. In this study, we investigated whether MYC and BCL 2 protein expression in tissue would predict survival in DLBCL. The study included 106 cases of de novo DLBCL treated with rituximab and cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) or CHOP‐like regimens. The results were validated on an independent cohort of 205 DLBCL patients. Patients with low expression of BCL 2 (≤30%) and MYC (≤50%) had the best prognosis, whereas those with high BCL 2 (>30%) and MYC (>50%) had the worst outcome. In multivariate analysis, the combination of the BCL 2 and MYC was an independent predictor of overall survival (OS) and event‐free survival (EFS) (P = 0·015 and P = 0·005, respectively). The risk of death was nine times greater for patients with high BCL 2 and MYC compared to those with low expression. High BCL 2 and MYC was a strong predictor of poor OS (P < 0·001) and EFS (P = 0·0017) in patients with the germinal centre B‐cell (GCB) type, but not in the non‐GCB type. In DLBCL, high co‐expression of MYC and BCL 2 was an independent predictor of poor survival, and could be used to stratify patients for risk‐adapted therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bjh.12763

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 166

Metadata

Authors
Perry, A. M., Alvarado‐Bernal, Y., Laurini, J. A., Smith, L. M., Slack, G. W., Tan, K. L., Sehn, L. H., Fu, K., Aoun, P., Greiner, T. C., Chan, W. C., Bierman, P. J., Bociek, R. G., Armitage, J. O., Vose, J. M., Gascoyne, R. D., & Weisenburger, D. D.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2014-02-08
Volume
165
Issue
3
Pages
382-391
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2007050465
Cited by
166
References
1
FWCI
20.94
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MYC and BCL 2 protein expression predicts survival in patients with diffuse large B‐cell lymphoma treated with rituximab. https://app.cochat.ai/papers/10.1111/bjh.12763
The paper
Perry, A. M., Alvarado‐Bernal, Y., Laurini, J. A., Smith, L. M., Slack, G. W., Tan, K. L., Sehn, L. H., Fu, K., Aoun, P., Greiner, T. C., Chan, W. C., Bierman, P. J., Bociek, R. G., Armitage, J. O., Vose, J. M., Gascoyne, R. D., & Weisenburger, D. D. (2014). MYC and BCL 2 protein expression predicts survival in patients with diffuse large B‐cell lymphoma treated with rituximab. British Journal of Haematology. https://doi.org/10.1111/bjh.12763

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.